Clinical Trial Update: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis [Phase 2]

View source ↗

Summary

EP262's Phase 2a randomized, double-blind, placebo-controlled study in subjects with atopic dermatitis has completed, with results posted and evaluating safety,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• EP262

Snippet

Sponsor: Escient Pharmaceuticals, Inc | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2025-08-24